Abstract
In an earlier study, we found PBP inhibited the progress of adjuvant-induced arthritis (AA). This study was aimed at evaluating the inhibitory effects of PBP in terms of NF-κB activation by using immunohistochemical and immunofluorescent technique in vitro and in vivo. IL-1β and TNF-α in serum were detected by method of ELISA. Immunofluorescent results showed that PBP inhibited NF-κB p65 translocation into nucleus. In vivo imaging showed that treatment with PBP decreased the enzyme labeling signal of NF-κB p65. Immunohistochemical staining revealed that PBP suppressed production of NF-κB p65 subunit in the joints and attenuated the productions of IL-1β and TNF-α in serum from AA. Moreover, NF-κB p65 nucleus translocation was prevented by simultaneous incubation with PBP and PGE2 was decreased by PBP through a feedback cycle. We report the first confirmation of the mimotope of PGE2 receptor EP4 modulatory action.
Keywords: Cytokine, inflammation, modulator, NF-κB, PGE2 binding peptide, rheumatoid arthritis, cyclooxygenase-2 (COX-2), interleukin (IL)-1, cytokines, EP4 receptor
Protein & Peptide Letters
Title: Prostaglandin E2 Binding Peptide: a Potential Modulatory Agent which Acts Through Suppressing NF-kappaB Signaling in RA
Volume: 19 Issue: 2
Author(s): Dongmei Yan, Weihai Peng, Xiangfeng Zhao, Xiao Han, Qihui Liu, Peng Li, Bairong Du and Xun Zhu
Affiliation:
Keywords: Cytokine, inflammation, modulator, NF-κB, PGE2 binding peptide, rheumatoid arthritis, cyclooxygenase-2 (COX-2), interleukin (IL)-1, cytokines, EP4 receptor
Abstract: In an earlier study, we found PBP inhibited the progress of adjuvant-induced arthritis (AA). This study was aimed at evaluating the inhibitory effects of PBP in terms of NF-κB activation by using immunohistochemical and immunofluorescent technique in vitro and in vivo. IL-1β and TNF-α in serum were detected by method of ELISA. Immunofluorescent results showed that PBP inhibited NF-κB p65 translocation into nucleus. In vivo imaging showed that treatment with PBP decreased the enzyme labeling signal of NF-κB p65. Immunohistochemical staining revealed that PBP suppressed production of NF-κB p65 subunit in the joints and attenuated the productions of IL-1β and TNF-α in serum from AA. Moreover, NF-κB p65 nucleus translocation was prevented by simultaneous incubation with PBP and PGE2 was decreased by PBP through a feedback cycle. We report the first confirmation of the mimotope of PGE2 receptor EP4 modulatory action.
Export Options
About this article
Cite this article as:
Yan Dongmei, Peng Weihai, Zhao Xiangfeng, Han Xiao, Liu Qihui, Li Peng, Du Bairong and Zhu Xun, Prostaglandin E2 Binding Peptide: a Potential Modulatory Agent which Acts Through Suppressing NF-kappaB Signaling in RA, Protein & Peptide Letters 2012; 19 (2) . https://dx.doi.org/10.2174/092986612799080329
DOI https://dx.doi.org/10.2174/092986612799080329 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Anticancer Activity of 2-Aryl-6-diethylaminoquinazolinone Derivatives
Letters in Drug Design & Discovery Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry Positron Emission Tomography for Neck Evaluation Following Definitive Treatment with Chemoradiotherapy for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Reviews on Recent Clinical Trials Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Immunity to Tumour Antigens
Current Pharmaceutical Design Antimutagenic, Antiproliferative and Antioxidant Properties of Sea Grape Leaf Extract Fractions (<i>Coccoloba uvifera</i> L.)
Anti-Cancer Agents in Medicinal Chemistry Peptide Nucleic Acids with a Structurally Biased Backbone. Updated Review and Emerging Challenges
Current Topics in Medicinal Chemistry Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Molecular Docking and Dynamic Simulation Studies of Terpenoids of I. wightii (Bentham) H. Hara against Acetylcholinesterase and Histone Deacetylase3 Receptors
Current Computer-Aided Drug Design Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Dantrolene Potentiates the Antineoplastic Effect of Sorafenib in Hepatocellular Carcinoma via Targeting Ca<sup>+2</sup>/PI3K Signaling Pathway
Current Molecular Pharmacology Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Natural Products as Leads for Tuberculosis Drug Development
Current Topics in Medicinal Chemistry KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine Peptides in Oral Diseases
Current Pharmaceutical Design